Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects

Purpose Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interaction, previously assessed via physiologicall...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology Jg. 84; H. 4; S. 749 - 757
Hauptverfasser:	Aslanis, Vassilios, Umehara, Kenichi, Huth, Felix, Ouatas, Taoufik, Bharathy, Savita, Butler, Andrew Avigdor, Zhou, Wen, Gadbaw, Brian
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2019 Springer Nature B.V
Schlagworte:	Adult Antifungal agents Cancer Research Cytochrome P-450 CYP2C9 - metabolism Cytochrome P-450 CYP3A - metabolism Cytochrome P450 Dose-Response Relationship, Drug Drug Administration Schedule Drug Interactions Enzyme Inhibitors - pharmacokinetics Female Fluconazole Fluconazole - pharmacokinetics Half-Life Healthy Volunteers Humans Inhibitor drugs Janus Kinases - metabolism Male Medicine Medicine & Public Health Metabolic Clearance Rate - drug effects Middle Aged Oncology Original Article Pharmacology/Toxicology Pyrazoles - pharmacokinetics Signal Transduction - drug effects Targeted cancer therapy Ruxolitinib CYP2C9 Physiologically based pharmacokinetic model Fluconazole CYP3A4 Drug–drug interaction
ISSN:	0344-5704, 1432-0843, 1432-0843
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Purpose Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interaction, previously assessed via physiologically based pharmacokinetic (PBPK) models, was confirmed in an open-label, phase 1 study in healthy subjects. Methods The effect of multiple doses (200 mg) of fluconazole on single-dose (10 mg) PK of ruxolitinib was investigated including evaluation of the safety and tolerability. The PK parameters of ruxolitinib alone (reference) were compared to those of ruxolitinib combined with fluconazole (test). The point estimate and corresponding two-sided 90% confidence interval for the difference between means of test and reference parameters were determined. Results All enrolled subjects ( N = 15) completed the study. When coadministered with fluconazole, geometric means of ruxolitinib PK parameters C max , AUC last , and AUC inf increased by 47%, 234%, and 232%, respectively, vs ruxolitinib alone. The median T max decreased slightly, apparent clearance decreased approximately threefold, and elimination half-life increased approximately 2.5-fold, upon ruxolitinib administration with fluconazole vs ruxolitinib alone. These results were consistent with the prospective predictions from a SimCYP PBPK model. Adverse events (AEs) were reported in six subjects (none were suspected to be related to ruxolitinib); no death or on-treatment serious AE was reported. Conclusions Coadministration of ruxolitinib with fluconazole significantly increased ruxolitinib systemic exposure; however, no AEs were attributed to ruxolitinib. Concomitant use of ruxolitinib with fluconazole (dose ≤ 200 mg) may require dose reduction/modification of ruxolitinib.
AbstractList	Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interaction, previously assessed via physiologically based pharmacokinetic (PBPK) models, was confirmed in an open-label, phase 1 study in healthy subjects. The effect of multiple doses (200 mg) of fluconazole on single-dose (10 mg) PK of ruxolitinib was investigated including evaluation of the safety and tolerability. The PK parameters of ruxolitinib alone (reference) were compared to those of ruxolitinib combined with fluconazole (test). The point estimate and corresponding two-sided 90% confidence interval for the difference between means of test and reference parameters were determined. All enrolled subjects (N = 15) completed the study. When coadministered with fluconazole, geometric means of ruxolitinib PK parameters C , AUC , and AUC increased by 47%, 234%, and 232%, respectively, vs ruxolitinib alone. The median T decreased slightly, apparent clearance decreased approximately threefold, and elimination half-life increased approximately 2.5-fold, upon ruxolitinib administration with fluconazole vs ruxolitinib alone. These results were consistent with the prospective predictions from a SimCYP PBPK model. Adverse events (AEs) were reported in six subjects (none were suspected to be related to ruxolitinib); no death or on-treatment serious AE was reported. Coadministration of ruxolitinib with fluconazole significantly increased ruxolitinib systemic exposure; however, no AEs were attributed to ruxolitinib. Concomitant use of ruxolitinib with fluconazole (dose ≤ 200 mg) may require dose reduction/modification of ruxolitinib. Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interaction, previously assessed via physiologically based pharmacokinetic (PBPK) models, was confirmed in an open-label, phase 1 study in healthy subjects.PURPOSERuxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interaction, previously assessed via physiologically based pharmacokinetic (PBPK) models, was confirmed in an open-label, phase 1 study in healthy subjects.The effect of multiple doses (200 mg) of fluconazole on single-dose (10 mg) PK of ruxolitinib was investigated including evaluation of the safety and tolerability. The PK parameters of ruxolitinib alone (reference) were compared to those of ruxolitinib combined with fluconazole (test). The point estimate and corresponding two-sided 90% confidence interval for the difference between means of test and reference parameters were determined.METHODSThe effect of multiple doses (200 mg) of fluconazole on single-dose (10 mg) PK of ruxolitinib was investigated including evaluation of the safety and tolerability. The PK parameters of ruxolitinib alone (reference) were compared to those of ruxolitinib combined with fluconazole (test). The point estimate and corresponding two-sided 90% confidence interval for the difference between means of test and reference parameters were determined.All enrolled subjects (N = 15) completed the study. When coadministered with fluconazole, geometric means of ruxolitinib PK parameters Cmax, AUClast, and AUCinf increased by 47%, 234%, and 232%, respectively, vs ruxolitinib alone. The median Tmax decreased slightly, apparent clearance decreased approximately threefold, and elimination half-life increased approximately 2.5-fold, upon ruxolitinib administration with fluconazole vs ruxolitinib alone. These results were consistent with the prospective predictions from a SimCYP PBPK model. Adverse events (AEs) were reported in six subjects (none were suspected to be related to ruxolitinib); no death or on-treatment serious AE was reported.RESULTSAll enrolled subjects (N = 15) completed the study. When coadministered with fluconazole, geometric means of ruxolitinib PK parameters Cmax, AUClast, and AUCinf increased by 47%, 234%, and 232%, respectively, vs ruxolitinib alone. The median Tmax decreased slightly, apparent clearance decreased approximately threefold, and elimination half-life increased approximately 2.5-fold, upon ruxolitinib administration with fluconazole vs ruxolitinib alone. These results were consistent with the prospective predictions from a SimCYP PBPK model. Adverse events (AEs) were reported in six subjects (none were suspected to be related to ruxolitinib); no death or on-treatment serious AE was reported.Coadministration of ruxolitinib with fluconazole significantly increased ruxolitinib systemic exposure; however, no AEs were attributed to ruxolitinib. Concomitant use of ruxolitinib with fluconazole (dose ≤ 200 mg) may require dose reduction/modification of ruxolitinib.CONCLUSIONSCoadministration of ruxolitinib with fluconazole significantly increased ruxolitinib systemic exposure; however, no AEs were attributed to ruxolitinib. Concomitant use of ruxolitinib with fluconazole (dose ≤ 200 mg) may require dose reduction/modification of ruxolitinib. Purpose Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interaction, previously assessed via physiologically based pharmacokinetic (PBPK) models, was confirmed in an open-label, phase 1 study in healthy subjects. Methods The effect of multiple doses (200 mg) of fluconazole on single-dose (10 mg) PK of ruxolitinib was investigated including evaluation of the safety and tolerability. The PK parameters of ruxolitinib alone (reference) were compared to those of ruxolitinib combined with fluconazole (test). The point estimate and corresponding two-sided 90% confidence interval for the difference between means of test and reference parameters were determined. Results All enrolled subjects ( N = 15) completed the study. When coadministered with fluconazole, geometric means of ruxolitinib PK parameters C max , AUC last , and AUC inf increased by 47%, 234%, and 232%, respectively, vs ruxolitinib alone. The median T max decreased slightly, apparent clearance decreased approximately threefold, and elimination half-life increased approximately 2.5-fold, upon ruxolitinib administration with fluconazole vs ruxolitinib alone. These results were consistent with the prospective predictions from a SimCYP PBPK model. Adverse events (AEs) were reported in six subjects (none were suspected to be related to ruxolitinib); no death or on-treatment serious AE was reported. Conclusions Coadministration of ruxolitinib with fluconazole significantly increased ruxolitinib systemic exposure; however, no AEs were attributed to ruxolitinib. Concomitant use of ruxolitinib with fluconazole (dose ≤ 200 mg) may require dose reduction/modification of ruxolitinib. PurposeRuxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9. The magnitude of this interaction, previously assessed via physiologically based pharmacokinetic (PBPK) models, was confirmed in an open-label, phase 1 study in healthy subjects.MethodsThe effect of multiple doses (200 mg) of fluconazole on single-dose (10 mg) PK of ruxolitinib was investigated including evaluation of the safety and tolerability. The PK parameters of ruxolitinib alone (reference) were compared to those of ruxolitinib combined with fluconazole (test). The point estimate and corresponding two-sided 90% confidence interval for the difference between means of test and reference parameters were determined.ResultsAll enrolled subjects (N = 15) completed the study. When coadministered with fluconazole, geometric means of ruxolitinib PK parameters Cmax, AUClast, and AUCinf increased by 47%, 234%, and 232%, respectively, vs ruxolitinib alone. The median Tmax decreased slightly, apparent clearance decreased approximately threefold, and elimination half-life increased approximately 2.5-fold, upon ruxolitinib administration with fluconazole vs ruxolitinib alone. These results were consistent with the prospective predictions from a SimCYP PBPK model. Adverse events (AEs) were reported in six subjects (none were suspected to be related to ruxolitinib); no death or on-treatment serious AE was reported.ConclusionsCoadministration of ruxolitinib with fluconazole significantly increased ruxolitinib systemic exposure; however, no AEs were attributed to ruxolitinib. Concomitant use of ruxolitinib with fluconazole (dose ≤ 200 mg) may require dose reduction/modification of ruxolitinib.
Author	Umehara, Kenichi Huth, Felix Butler, Andrew Avigdor Aslanis, Vassilios Bharathy, Savita Zhou, Wen Ouatas, Taoufik Gadbaw, Brian
Author_xml	– sequence: 1 givenname: Vassilios surname: Aslanis fullname: Aslanis, Vassilios organization: Novartis AG – sequence: 2 givenname: Kenichi surname: Umehara fullname: Umehara, Kenichi organization: Novartis Institutes for Biomedical Research – sequence: 3 givenname: Felix surname: Huth fullname: Huth, Felix email: felix.huth@novartis.com organization: Novartis Institutes for Biomedical Research, Translational Medicine-Pharmacokinetic Sciences, Novartis Pharma AG – sequence: 4 givenname: Taoufik surname: Ouatas fullname: Ouatas, Taoufik organization: Novartis AG – sequence: 5 givenname: Savita surname: Bharathy fullname: Bharathy, Savita organization: Novartis Pharmaceuticals Corporation – sequence: 6 givenname: Andrew Avigdor surname: Butler fullname: Butler, Andrew Avigdor organization: Novartis Pharmaceuticals Corporation – sequence: 7 givenname: Wen surname: Zhou fullname: Zhou, Wen organization: Novartis Pharmaceuticals Corporation – sequence: 8 givenname: Brian surname: Gadbaw fullname: Gadbaw, Brian organization: Novartis Pharmaceuticals Corporation
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31324935$$D View this record in MEDLINE/PubMed
BookMark	eNp9kTtvFTEQRi0URG4Cf4ACWaKhWRi_dtclinhJQTRQW7avl_jKay9-SAm_Hic3gJQilYs5Zzwz3xk6iSk6hF4SeEsApncFgM4wAJEDMAnTQJ6gHeGMDjBzdoJ2wDgfxAT8FJ2VcgAAThh7hk4ZYZRLJnbIf22h-i04rPerj77UrKtPseC04CU0m6L-nXrZR5udLg5vQZdVY3e9pdKywzXh3K5T8LXrpnP4yulQr256x94bl2YOztbyHD1ddCjuxf17jn58_PD94vNw-e3Tl4v3l4Nlk6iDFWYUy6iJNlL2_Yw1fTfJJJspXxwHQiR1ds_EpIGOkzQchDDdWmZNqGHn6M2x75bTr-ZKVasv1oWgo0utKEpHIkcxj2NHXz9AD6nl2Ke7pYASOo-iU6_uqWZWt1db9qvON-rvETtAj4DNqZTsln8IAXWblDompXpS6i4pRbo0P5Csr3en7wn48LjKjmrp_8SfLv8f-xHrD54Rp-8
CitedBy_id	crossref_primary_10_1016_j_jchromb_2023_123917 crossref_primary_10_1080_14740338_2025_2490837 crossref_primary_10_1177_10781552221110826 crossref_primary_10_1007_s13318_024_00917_0 crossref_primary_10_1016_j_jtct_2024_02_018 crossref_primary_10_1007_s00280_022_04494_4 crossref_primary_10_1007_s40262_023_01225_7 crossref_primary_10_1038_s41392_024_01987_x crossref_primary_10_1016_j_jtct_2025_04_018 crossref_primary_10_7759_cureus_81725 crossref_primary_10_2147_DDDT_S354270 crossref_primary_10_3390_pharmaceutics14122556 crossref_primary_10_1016_S2352_3026_21_00232_5 crossref_primary_10_3389_fphar_2022_962731 crossref_primary_10_1016_j_biopha_2021_111642 crossref_primary_10_1016_j_dmd_2025_100141 crossref_primary_10_1055_s_0041_1740950 crossref_primary_10_1007_s00280_021_04351_w crossref_primary_10_1111_apt_16489 crossref_primary_10_1007_s00277_021_04727_1 crossref_primary_10_1007_s00280_022_04464_w
Cites_doi	10.1186/2050-7771-1-5 10.1007/s15010-017-1042-z 10.1038/leu.2016.148 10.1056/NEJMoa1409002 10.1128/AAC.48.3.693-715.2004 10.1056/NEJMoa1110557 10.1002/jcph.102 10.1038/leu.2013.205 10.2165/00003088-199733010-00005 10.1177/0091270011405663 10.1002/cpt.30 10.1038/onc.2012.347 10.1016/j.cytogfr.2013.01.004 10.1016/j.bcp.2011.12.024 10.1177/0091270010389469 10.1002/cpdd.71 10.1124/dmd.110.033787 10.13181/mji.v20i3.453 10.1515/dmpt-2018-0042
ContentType	Journal Article
Copyright	Springer-Verlag GmbH Germany, part of Springer Nature 2019 Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved.
Copyright_xml	– notice: Springer-Verlag GmbH Germany, part of Springer Nature 2019 – notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8
DOI	10.1007/s00280-019-03907-1
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic Oncogenes and Growth Factors Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
EISSN	1432-0843
EndPage	757
ExternalDocumentID	31324935 10_1007_s00280_019_03907_1
Genre	Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I
GroupedDBID	--- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO
ID	FETCH-LOGICAL-c375t-c5b65f6a1ab99028bcb3909393824fe401192ecd357a02679b4055b5b6f8a12b3
IEDL.DBID	RSV
ISICitedReferencesCount	25
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000488659900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0344-5704 1432-0843
IngestDate	Fri Sep 05 06:14:42 EDT 2025 Sat Nov 08 16:47:38 EST 2025 Mon Jul 21 06:05:02 EDT 2025 Sat Nov 29 04:45:34 EST 2025 Tue Nov 18 21:20:31 EST 2025 Fri Feb 21 02:33:15 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	Ruxolitinib CYP2C9 Physiologically based pharmacokinetic model Fluconazole CYP3A4 Drug–drug interaction
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c375t-c5b65f6a1ab99028bcb3909393824fe401192ecd357a02679b4055b5b6f8a12b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
PMID	31324935
PQID	2260212865
PQPubID	48447
PageCount	9
ParticipantIDs	proquest_miscellaneous_2261965866 proquest_journals_2260212865 pubmed_primary_31324935 crossref_primary_10_1007_s00280_019_03907_1 crossref_citationtrail_10_1007_s00280_019_03907_1 springer_journals_10_1007_s00280_019_03907_1
PublicationCentury	2000
PublicationDate	20191000 2019-10-00 20191001
PublicationDateYYYYMMDD	2019-10-01
PublicationDate_xml	– month: 10 year: 2019 text: 20191000
PublicationDecade	2010
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: Heidelberg
PublicationTitle	Cancer chemotherapy and pharmacology
PublicationTitleAbbrev	Cancer Chemother Pharmacol
PublicationTitleAlternate	Cancer Chemother Pharmacol
PublicationYear	2019
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	CR2 Vannucchi, Kiladjian, Griesshammer, Masszi, Durrant, Passamonti, Harrison, Pane, Zachee, Mesa, He, Jones, Garrett, Li, Pirron, Habr, Verstovsek (CR9) 2015; 372 Furqan, Mukhi, Lee, Liu (CR6) 2013; 1 Zhou, Georgeon, Moser, Moore, Caflisch, Hantschel (CR1) 2014; 28 Chen, Williams, Sandor, Yeleswaram (CR11) 2013; 53 Shi, Chen, Emm, Scherle, McGee, Lo, Landman, McKeever, Punwani, Williams, Yeleswaram (CR13) 2012; 52 CR16 CR24 Hasselbalch (CR3) 2013; 24 Seavey, Dobrzanski (CR4) 2012; 83 CR23 Vainchenker, Constantinescu (CR5) 2013; 32 Bellmann, Smuszkiewicz (CR17) 2017; 45 Susilo, Setiawati, Darmansjah, Indarti, Kusuma (CR19) 2011; 20 CR21 Johnson, MacDougall, Ostrosky-Zeichner, Perfect, Rex (CR18) 2004; 48 Debruyne (CR22) 1997; 33 Shilling, Nedza, Emm, Diamond, McKeever, Punwani, Williams, Arvanitis, Galya, Li, Shepard, Rodgers, Yue, Yeleswaram (CR10) 2010; 38 Umehara, Huth, Jin, Schiller, Aslanis, Heimbach, He (CR14) 2019 Shi, Fraczkiewicz, Williams, Yeleswaram (CR15) 2015; 97 Gupta, Chow, Wang, Kaplan, Chan, Alvey, Ni, Ndongo, LaBadie, Krishnaswami (CR20) 2014; 3 Verstovsek, Mesa, Gotlib, Levy, Gupta, DiPersio, Catalano, Deininger, Miller, Silver, Talpaz, Winton, Harvey, Arcasoy, Hexner, Lyons, Paquette, Raza, Vaddi, Erickson-Viitanen, Koumenis, Sun, Sandor, Kantarjian (CR7) 2012; 366 Harrison, Vannucchi, Kiladjian, Al-Ali, Gisslinger, Knoops, Cervantes, Jones, Sun, McQuitty, Stalbovskaya, Gopalakrishna, Barbui (CR8) 2016; 30 Shi, Chen, McGee, Landman, Emm, Lo, Scherle, Punwani, Williams, Yeleswaram (CR12) 2011; 51 T Zhou (3907_CR1) 2014; 28 M Furqan (3907_CR6) 2013; 1 MM Seavey (3907_CR4) 2012; 83 JG Shi (3907_CR15) 2015; 97 3907_CR16 3907_CR21 3907_CR24 D Debruyne (3907_CR22) 1997; 33 3907_CR23 CN Harrison (3907_CR8) 2016; 30 3907_CR2 X Chen (3907_CR11) 2013; 53 R Bellmann (3907_CR17) 2017; 45 HC Hasselbalch (3907_CR3) 2013; 24 AD Shilling (3907_CR10) 2010; 38 P Gupta (3907_CR20) 2014; 3 JG Shi (3907_CR13) 2012; 52 K Umehara (3907_CR14) 2019 S Verstovsek (3907_CR7) 2012; 366 AM Vannucchi (3907_CR9) 2015; 372 JG Shi (3907_CR12) 2011; 51 W Vainchenker (3907_CR5) 2013; 32 MD Johnson (3907_CR18) 2004; 48 J Susilo (3907_CR19) 2011; 20
References_xml	– ident: CR21 – volume: 1 start-page: 5 year: 2013 ident: CR6 article-title: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application publication-title: Biomark Res doi: 10.1186/2050-7771-1-5 – volume: 45 start-page: 737 year: 2017 end-page: 779 ident: CR17 article-title: Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients publication-title: Infection doi: 10.1007/s15010-017-1042-z – volume: 30 start-page: 1701 year: 2016 end-page: 1707 ident: CR8 article-title: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis publication-title: Leukemia doi: 10.1038/leu.2016.148 – ident: CR2 – volume: 372 start-page: 426 year: 2015 end-page: 435 ident: CR9 article-title: Ruxolitinib versus standard therapy for the treatment of polycythemia vera publication-title: N Engl J Med doi: 10.1056/NEJMoa1409002 – ident: CR16 – volume: 48 start-page: 693 year: 2004 end-page: 715 ident: CR18 article-title: Combination antifungal therapy publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.3.693-715.2004 – volume: 366 start-page: 799 year: 2012 end-page: 807 ident: CR7 article-title: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1110557 – volume: 53 start-page: 721 year: 2013 end-page: 730 ident: CR11 article-title: Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF) publication-title: J Clin Pharmacol doi: 10.1002/jcph.102 – volume: 28 start-page: 404 year: 2014 end-page: 407 ident: CR1 article-title: Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) publication-title: Leukemia doi: 10.1038/leu.2013.205 – volume: 33 start-page: 52 year: 1997 end-page: 77 ident: CR22 article-title: Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199733010-00005 – volume: 52 start-page: 809 year: 2012 end-page: 818 ident: CR13 article-title: The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers publication-title: J Clin Pharmacol doi: 10.1177/0091270011405663 – volume: 97 start-page: 177 year: 2015 end-page: 185 ident: CR15 article-title: Predicting drug–drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.30 – volume: 32 start-page: 2601 year: 2013 end-page: 2613 ident: CR5 article-title: JAK/STAT signaling in hematological malignancies publication-title: Oncogene doi: 10.1038/onc.2012.347 – volume: 24 start-page: 133 year: 2013 end-page: 145 ident: CR3 article-title: The role of cytokines in the initiation and progression of myelofibrosis publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2013.01.004 – volume: 83 start-page: 1136 year: 2012 end-page: 1145 ident: CR4 article-title: The many faces of Janus kinase publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2011.12.024 – volume: 51 start-page: 1644 year: 2011 end-page: 1654 ident: CR12 article-title: The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers publication-title: J Clin Pharmacol doi: 10.1177/0091270010389469 – volume: 3 start-page: 72 year: 2014 end-page: 77 ident: CR20 article-title: Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.71 – ident: CR24 – volume: 38 start-page: 2023 year: 2010 end-page: 2031 ident: CR10 article-title: Metabolism, excretion, and pharmacokinetics of [ C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans publication-title: Drug Metab Dispos doi: 10.1124/dmd.110.033787 – volume: 20 start-page: 205 year: 2011 end-page: 211 ident: CR19 article-title: Low-dose ketoconazole-fluconazole combination versus fluconazole in single doses for the treatment of vaginal candidiasis publication-title: Med J Indones doi: 10.13181/mji.v20i3.453 – ident: CR23 – year: 2019 ident: CR14 article-title: Drug–drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions publication-title: Drug Metab Pers Ther doi: 10.1515/dmpt-2018-0042 – volume: 3 start-page: 72 year: 2014 ident: 3907_CR20 publication-title: Clin Pharmacol Drug Dev doi: 10.1002/cpdd.71 – volume: 45 start-page: 737 year: 2017 ident: 3907_CR17 publication-title: Infection doi: 10.1007/s15010-017-1042-z – volume: 33 start-page: 52 year: 1997 ident: 3907_CR22 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-199733010-00005 – volume: 52 start-page: 809 year: 2012 ident: 3907_CR13 publication-title: J Clin Pharmacol doi: 10.1177/0091270011405663 – volume: 51 start-page: 1644 year: 2011 ident: 3907_CR12 publication-title: J Clin Pharmacol doi: 10.1177/0091270010389469 – volume: 20 start-page: 205 year: 2011 ident: 3907_CR19 publication-title: Med J Indones doi: 10.13181/mji.v20i3.453 – volume: 372 start-page: 426 year: 2015 ident: 3907_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa1409002 – volume: 24 start-page: 133 year: 2013 ident: 3907_CR3 publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2013.01.004 – volume: 48 start-page: 693 year: 2004 ident: 3907_CR18 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.3.693-715.2004 – volume: 32 start-page: 2601 year: 2013 ident: 3907_CR5 publication-title: Oncogene doi: 10.1038/onc.2012.347 – volume: 366 start-page: 799 year: 2012 ident: 3907_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa1110557 – year: 2019 ident: 3907_CR14 publication-title: Drug Metab Pers Ther doi: 10.1515/dmpt-2018-0042 – volume: 83 start-page: 1136 year: 2012 ident: 3907_CR4 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2011.12.024 – volume: 97 start-page: 177 year: 2015 ident: 3907_CR15 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.30 – ident: 3907_CR2 – volume: 53 start-page: 721 year: 2013 ident: 3907_CR11 publication-title: J Clin Pharmacol doi: 10.1002/jcph.102 – volume: 30 start-page: 1701 year: 2016 ident: 3907_CR8 publication-title: Leukemia doi: 10.1038/leu.2016.148 – ident: 3907_CR21 – ident: 3907_CR16 – ident: 3907_CR23 – ident: 3907_CR24 – volume: 1 start-page: 5 year: 2013 ident: 3907_CR6 publication-title: Biomark Res doi: 10.1186/2050-7771-1-5 – volume: 38 start-page: 2023 year: 2010 ident: 3907_CR10 publication-title: Drug Metab Dispos doi: 10.1124/dmd.110.033787 – volume: 28 start-page: 404 year: 2014 ident: 3907_CR1 publication-title: Leukemia doi: 10.1038/leu.2013.205
SSID	ssj0004133
Score	2.3912218
Snippet	Purpose Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib... Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure... PurposeRuxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9. Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib...
SourceID	proquest pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	749
SubjectTerms	Adult Antifungal agents Cancer Research Cytochrome P-450 CYP2C9 - metabolism Cytochrome P-450 CYP3A - metabolism Cytochrome P450 Dose-Response Relationship, Drug Drug Administration Schedule Drug Interactions Enzyme Inhibitors - pharmacokinetics Female Fluconazole Fluconazole - pharmacokinetics Half-Life Healthy Volunteers Humans Inhibitor drugs Janus Kinases - metabolism Male Medicine Medicine & Public Health Metabolic Clearance Rate - drug effects Middle Aged Oncology Original Article Pharmacology/Toxicology Pyrazoles - pharmacokinetics Signal Transduction - drug effects Targeted cancer therapy
SummonAdditionalLinks	– databaseName: Public Health Database dbid: 8C1 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB5RqKpe-qDQbqHIlSouXYs4sZP4hCpUxAW0Bypxi2zHllaCZNnsVmx_fT2OdyOEyqVnP2JlHh7P4xuAbyZTUvNCU50YS7mtHZVJLalWXjEoZ9PcuNBsori6Km9u5CQ63LqYVrnWiUFR161BH_mJNxMQjbzMxensnmLXKIyuxhYaL2CHpQlHwSzPhhQPr6D79sicU1EkPBbNhNK5EFP0D2lJE__sLyh7fDE9sTafRErDBXT-9n-P_g7eRNOT_Oh55T1s2WYXXl3G4PouHE96GOvVmFwPVVndmByTyQBwvfoA08uYhUjUI-jdjrSOOMyBb9Sf1g9PG7RJO0tm3ka_U8Q-zFr0SJJFS-bLh5B610y1n0f6eswVCXggpFtq9A91e_Dr_Of12QWNLRuoyQqxoEboXLhcMaUl4sJoo_3flZnMypQ7yxFhLrWmzkShsPeV55NECO1XuVKxVGf7sN20jf0EJGcuTWupmeU1F1yrutAZz52wztqCqRGwNb0qE_HMsa3GbbVBYg40rjyNq0Djio3g-2bNrEfzeHb24ZqeVZTsrhqIOYKvm2EvkxhoUY1tl2EOAjWWeT6Cjz37bD6HUJlcZn71eM1Pw-b_Psvn589yAK9T5OWQZXgI24v50n6Bl-b3YtrNj4JU_AXozBN1 priority: 102 providerName: ProQuest
Title	Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
URI	https://link.springer.com/article/10.1007/s00280-019-03907-1 https://www.ncbi.nlm.nih.gov/pubmed/31324935 https://www.proquest.com/docview/2260212865 https://www.proquest.com/docview/2261965866
Volume	84
WOSCitedRecordID	wos000488659900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-0843 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004133 issn: 0344-5704 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbxQhEJ9oa4wvrdav03rBxPTFI1kWWJZHbdr40sulVnNvG2AhuUR3L7d3pudfX2A_Lk2rib7wwsCyMAMDM_MbgA-GKqmZ0FgnxmJmS4dlUkqsld8YlLNpZlxMNiGm03w-l7MuKKzpvd17k2TcqYdgt2gF9FdfiRN_URfY33n2_XGXB3G8_Pp9Fw1J2gTylDHMRcK6UJn7-7h9HN3RMe_YR-Oxc374fwN-Cgedmok-tXzxDB7Y6ggeX3SG9CM4mbWQ1dsJutpFYDUTdIJmOzDr7XNYXHQeh0jdgtltUO2QC_7ulfpd--pFFfTPxqKl18d_KmSvl3V4fUTrGq0219HNrlpoT4fa2MstitgfqNno8BbUvIBv52dXp19wl54BGyr4GhuuM-4yRZSWAQNGG-1_U1JJ85Q5ywKaXGpNSblQIc-V54mEc-1buVyRVNOXsFfVlX0NKCMuTUupiWUl40yrUmjKMsets1YQNQLSr1JhOuzykELjRzGgLsfJLvxkF3GyCzKCj0ObZYvc8Vfq437xi06Km8KrpgEBP8_4CN4P1V7-glFFVbbeRJoAyphn2QhetUwzfC7AYjJJfetJzyG7zv88ljf_Rv4WnqSByaKH4THsrVcb-w4emV_rRbMaw0MxF7HMfZmfkjHsfz6bzi7HUWpuANR0DgY
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoALj_JaKGAk6IW1yMNO4gNCqFC1ane1h0XqLdiOLa0EybLZhS4_it-Ix0k2qip664Gzn3E-j2fsmW8AXutYCsVSRVWgDWWmsFQEhaBKOsEgrYkSbX2yiXQ8zk5PxWQL_nSxMOhW2clEL6iLSuMd-TunJiAbeZbwD_MfFLNG4etql0KjgcWxWf9yJlv9_uiT-79voujg83T_kLZZBaiOU76kmquE20SGUgmkLlFaObtfxCLOImYNQxK0yOgi5qnE9EzuUwLOlWtlMxlGKnb9XoPryGSHxl6237uUuAOhScfMGOVpwNogHR-q598wneEuaOCGS2l4_iC8oN1eeJn1B97B3f9tqe7BnVa1Jh-bvXAftky5AzdHrfPADuxNGpru9ZBM-6izekj2yKQn8F4_gNmo9bIk8hy1cE0qSyz6-Jfyd-WKZyXq3LUhc2eDfJfEnM0rvHEly4osVmfetbCcKVePNPGma-L5Tki9Unj_VT-EL1eyIo9gu6xK8wRIEtooKoQKDSsYZ0oWqYpZYrmxxqShHEDY4SPXLV87pg35lm-Ypj2mcoep3GMqDwfwdtNm3rCVXFp7t8NP3kquOu_BM4BXm2Inc_AhSZamWvk6SESZJckAHjdw3QyHVKBMxK71sMNv3_m_5_L08rm8hFuH09FJfnI0Pn4GtyPcR96jche2l4uVeQ439M_lrF688DuSwNerxvVfsWxuXg
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouPMqjCwWMBL2wVvOwk_iAEGpZUZWu9lCk3oLt2NJKNFk2u9Dlp_HrGDvJRlVFbz1w9jPO5_GMPfMNwBsdS6FYqqgKtKHMFJaKoBBUSRQM0poo0dYnm0jH4-zsTEw24E8XC-PcKjuZ6AV1UWl3R76PaoJjI88Svm9bt4jJ4ejD7Ad1GaTcS2uXTqOByLFZ_ULzrX5_dIj_-m0UjT6dHnymbYYBquOUL6jmKuE2kaFUwtGYKK1igTa-iLOIWcMcIVpkdBHzVLpUTfhZAecKW9lMhpGKsd9bcDuNEcUuSv2gdy_Bw6FJzcwY5WnA2oAdH7bn3zPRiBc0wOFSGl4-FK9ouldeaf3hN7r_Py_bA7jXqtzkY7NHHsKGKbdh66R1KtiGvUlD370aktM-Gq0ekj0y6Ym9V49getJ6XxJ5iXK4JpUl1vn-l_J3hcXT0unitSEztE3OJTEXs8rdxJJFRebLC-9yWE4V1iNNHOqKeB4UUi-VuxerH8PXG1mRJ7BZVqXZAZKENooKoULDCsaZkkWqYpZYbqwxaSgHEHZYyXXL4-7SiXzP1wzUHl854iv3-MrDAbxbt5k1LCbX1t7tsJS3Eq3OeyAN4PW6GGWRe2CSpamWvo4jqMySZABPG-iuh3MUoUzE2HrYYbnv_N9zeXb9XF7BFsI5_3I0Pn4OdyO3pbyj5S5sLuZL8wLu6J-LaT1_6TcngW83Deu_FQ93Iw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multiple+administrations+of+fluconazole+increase+plasma+exposure+to+ruxolitinib+in+healthy+adult+subjects&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Aslanis%2C+Vassilios&rft.au=Umehara%2C+Kenichi&rft.au=Huth%2C+Felix&rft.au=Ouatas%2C+Taoufik&rft.date=2019-10-01&rft.eissn=1432-0843&rft.volume=84&rft.issue=4&rft.spage=749&rft_id=info:doi/10.1007%2Fs00280-019-03907-1&rft_id=info%3Apmid%2F31324935&rft.externalDocID=31324935
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon